|
1
|
Lowenfels AB and Maisonneuve P:
Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol.
34:238–244. 2004. View Article : Google Scholar
|
|
2
|
Bayraktar S and Rocha-Lima CM: Advanced or
metastatic pancreatic cancer: molecular targeted therapies. Mt
Sinai J Med. 77:606–619. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
ACS. Cancer Facts and Figures. 2012,
Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf.
(Accessed Jan 18, 2012)
|
|
4
|
Freelove R and Walling AD: Pancreatic
cancer: diagnosis and management. Am Fam Physician. 73:485–492.
2006.PubMed/NCBI
|
|
5
|
Hezel AF, Kimmelman AC, Stanger BZ,
Bardeesy N and Depinho RA: Genetics and biology of pancreatic
ductal adenocarcinoma. Genes Dev. 20:1218–1249. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar
|
|
7
|
Cartwright T, Richards D and Boehm K:
Cancer of the pancreas: are we making progress? a review of studies
in the US Oncology Research Network. Cancer Control. 15:308–313.
2008.PubMed/NCBI
|
|
8
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD:
Improvements in survival and clinical benefit with gemcitabine as
first-line therapy for patients with advanced pancreas cancer: a
randomized trial. J Clin Oncol. 15:24031997.PubMed/NCBI
|
|
9
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F,
Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P,
Montoto-Grillot C and Ducreux M; Groupe Tumeurs Digestives of
Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bemis DL, Capodice JL, Desai M, Katz AE
and Buttyan R: beta-carboline alkaloid-enriched extract from the
amazonian rain forest tree pao pereira suppresses prostate cancer
cells. J Soc Integr Oncol. 7:59–65. 2009.PubMed/NCBI
|
|
11
|
Beljanski M and Beljanski MS: Three
alkaloids as selective destroyers of cancer cells in mice. Synergy
with classic anticancer drugs. Oncology. 43:198–203. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cao R, Chen Q, Hou X, Chen H, Guan H, Ma
Y, Peng W and Xu A: Synthesis, acute toxicities, and antitumor
effects of novel 9-substituted beta-carboline derivatives. Bioorg
Med Chem. 12:4613–4623. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen Q, Chao R, Chen H, Hou X, Yan H, Zhou
S, Peng W and Xu A: Antitumor and neurotoxic effects of novel
harmine derivatives and structure-activity relationship analysis.
Int J Cancer. 114:675–682. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Puiseux F, Le Hir A, Goutarel R, Janot MM
and Lemen J: On the alkaloids of ‘pao-pereira’, Geissospermum laeve
(Vellozo) Baillon. Note III. Geissoschizoline, apogeissoschizine
and geissospermine. Ann Pharm Fr. 17:626–633. 1959.(In French).
|
|
15
|
Cole SP: Rapid chemosensitivity testing of
human lung tumor cells using the MTT assay. Cancer Chemother
Pharmacol. 17:259–263. 1986.PubMed/NCBI
|
|
16
|
Denizot F and Lang R: Rapid colorimetric
assay for cell growth and survival. Modifications to the
tetrazolium dye procedure giving improved sensitivity and
reliability. J Immunol Methods. 89:271–277. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chou T and Talalay P: Applications of the
median-effect principle for the assessment of low-dose risk of
carcinogens and for the quantitation of synergism and antagonism of
chemotherapeutic agents. New Avenues in Developmental Cancer
Chemotherapy. 8. Harrap KR and Connors TA: Academic Press; New
York, NY: pp. 37–64. 1987
|
|
18
|
Chou T, Rideout D, Chou J and Bertino J:
Chemotherapeutic synergism, potentiation and antagonism.
Encyclopedia of Human Biology. 2. Dulbecco R: Academic Press, Inc;
San Diego, CA: pp. 371–379. 1991
|
|
19
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eagle H, Foley GE, Koprowski H, Lazarus H,
Levine EM and Adams RA: Growth characteristics of virus-transformed
cells. Maximum population density, inhibition by normal cells,
serum requirement, growth in soft agar, and xenogeneic
transplantability. J Exp Med. 131:863–879. 1970. View Article : Google Scholar
|
|
21
|
Zeng G, Cai S, Liu Y and Wu GJ:
METCAM/MUC18 augments migration, invasion, and tumorigenicity of
human breast cancer SK-BR-3 cells. Gene. 492:229–238. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oettle H, Post S, Neuhaus P, Gellert K,
Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C,
Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K,
Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B
and Riess H: Adjuvant chemotherapy with gemcitabine vs observation
in patients undergoing curative-intent resection of pancreatic
cancer: a randomized controlled trial. JAMA. 297:267–277. 2007.
View Article : Google Scholar
|
|
23
|
Renouf D and Moore M: Evolution of
systemic therapy for advanced pancreatic cancer. Expert Rev
Anticancer Ther. 10:529–540. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rybak MJ: The pharmacokinetic and
pharmacodynamic properties of vancomycin. Clin Infect Dis. 42(Suppl
1): S35–S39. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mertz W: The essential trace elements.
Science. 213:1332–1338. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nyberg F, Hou SM, Pershagen G and Lambert
B: Dietary fruit and vegetables protect against somatic mutation in
vivo, but low or high intake of carotenoids does not.
Carcinogenesis. 24:689–696. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Donate F, Parry GC, Shaked Y, Hensley H,
Guan X, Beck I, Tel-Tsur Z, Plunkett ML, Manuia M, Shaw DE, Kerbel
RS and Mazar AP: Pharmacology of the novel antiangiogenic peptide
ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response
curve in several preclinical models of angiogenesis and tumor
growth. Clin Cancer Res. 14:2137–2144. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Celik I, Surucu O, Dietz C, Heymach JV,
Force J, Hoschele I, Becker CM, Folkman J and Kisker O: Therapeutic
efficacy of endostatin exhibits a biphasic dose-response curve.
Cancer Res. 65:11044–11050. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nishi M, Ohba S, Hirata K and Miyake H:
Dose-response relationship between coffee and the risk of pancreas
cancer. Jpn J Clin Oncol. 26:42–48. 1996. View Article : Google Scholar : PubMed/NCBI
|
